Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Mar;27(3):125-8.
doi: 10.1002/clc.4960270305.

Evolving targets for risk reduction in diabetes

Gregory M Caputo  1 , Joel B Braunstein, Roger S Blumenthal
Affiliations
Review

Evolving targets for risk reduction in diabetes

Gregory M Caputo et al. Clin Cardiol. 2004 Mar.

Abstract

Recent evidence shows that target low-density lipoprotein cholesterol should be less than 100 mg/dl in patients with diabetes, and that even those with initially low levels benefit from pharmacologic therapy. Recent studies document that blood pressures lower than the previous target of 140/90 mmHg are beneficial, in addition to providing observational evidence against a lower threshold of benefit. Evidence that addresses the effect of blood glucose on macrovascular disease risk in patients with diabetes is reviewed. Finally, recommendations are made regarding systematic changes in healthcare delivery that will facilitate risk reduction strategies in diabetes.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary artery disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229 - PubMed
    1. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 - PubMed
    1. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE Investigators: Cardiovascular events and their reduction with pravastatin in diabetic and glucose‐intolerant myocardial infarction survivors with average cholesterol levels : Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998; 98: 2513–2519 - PubMed
    1. Heart Protection Collaborative Group : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: A randomised placebo‐controlled trial. Lancet 2002; 360 - PubMed
    1. Collins R, Armitage J, Parish S, Sleight P, Peto R: MRC/BHF heart protection study of cholesterol‐lowering in 5,963 people with diabetes: A randomized placebo‐controlled trial. Lancet 2003; 361: 2005–2016 - PubMed